DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1

Information source: Universidad Autonoma de San Luis Potosí
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Retinopathy of Prematurity

Intervention: Injection of bevacizumab intravitreal (Avastin) (Procedure)

Phase: N/A

Status: Recruiting

Sponsored by: Universidad Autonoma de San Luis Potosí

Official(s) and/or principal investigator(s):
Rangel Ch Martha, Speciality, Principal Investigator, Affiliation: Universidad Autónoma de San Luis Potosí

Summary

The Retinopathy of Prematurity (ROP) is a Retina's pathology only of the premature baby, it's characterized for proliferation of vascular tissue that grow in the limit between the vascular retina and the avascular retina. The altered regulation of Vascular Endothelial Grow Factor (VEGF) has been proposed as one of the principal factor in the pathogenesis of the ROP. The ROP is classified for: location (zones I,II,III), extension (hours 1 to 12) and for stages (1,2,3,4a,4b,5) and features of the vessels (normal, pre-plus and plus). With the diagnosis of ROP type 1(ROP zone I any stage with plus, zone I stage 3 without plus, zone II stage 2 y 3 with plus) the treatment is begun and ROP type 2 is maintained in observation. The altered regulation of Vascular Endothelial Grow Factor (VEGF) has been proposed as one of the principal factors in the pathogenesis of ROP.

Clinical Details

Official title: Study of no Inferiority Between Two Doses (0.500mg and 0.625mg) of Bevacizumab Intravitreal in the Treatment of Retinopathy of Prematurity Type 1

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Regression of Retinopathy of prematurity

Detailed description: ustification: Before the treatment was with Cryotherapy and the standard gold is the laser, however the retina tissue is destroyed, and there is loss of visual field and as this procedure has need to be with general anesthesia, there may be trans and post surgical complications. Currently the intravitreal antiangiogenics are been employed (that inhibit the VEGF), specially the Bevacizumab, it's a quickly procedure with topic anesthesia and low price, with a good results. It's known that intravitreal bevacizumab arrives blood and there aren't reports of secondary efects in this moment, however, we want demonstrate that for the weight and volume of the premature baby's eye, we need a low dosis and then we will have less sistemic effect. HYPOTHESIS: The injection of 0. 500 mg of Bevacizumab intravitreal it isnt lower that 0. 625 mg of Bevacizumab intravitreal for the regression of ROP type 1 OBJECTIVE: Demonstrate that 0. 500mg of Bevacizumab intravitreal isn't inferior that 0. 625mg in the resolution of ROP type 1. METHODOLOGY: No inferiority study. ECCA. We are going to include premature patients prematures with less of 32SDG and/or 1500g and less of 36SDG with factors risk. They are going to be examined in the week fourth, with de diagnosis for ROP type 1, we are going to inject intravitreal Bevacizumab, with the dosis randomized (0. 500mg and 0. 625mg) and they are going to be examined another time at first week, two weeks, first month, and for the second to sixth month after the treatment, for warrant la resolution of ROP. The size simple is 30 patients for group (Dosis A and Dosis B). We are going to describe the date of the infection, and the age of the baby when the bevacizumab was inyected. When the ROP have been in regression, we are going to describe the date, and finally we are going to describe the age is going to be the baby she the ROP have been in regression. It is going to be important determine the concept of exit and failure. And finally demonstrate if the two dosage have a good result

Eligibility

Minimum age: 1 Month. Maximum age: 4 Months. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Prematurity, low weight, oxygen, retinopathy of prematurity type 1

Exclusion Criteria:

- Retinopathy of prematurity type 2, retinopathy of prematurity stage 4 or 5

Locations and Contacts

Hospital Central Dr. "IMP", Mexico, San Luis Potosí 78240, Mexico; Recruiting
Rangel Martha, Dr, Phone: 014448262300, Ext: 6688, Email: gisorangel@gmail.com
Sánchez Martín, M.C, Phone: 014448262300, Ext: 6688, Email: jemarsan7@hotmail.com
MARTHA RANGEL, DR, Principal Investigator

Hospital Central Dr."IMP", Mexico, San Luis Potosí, Mexico; Recruiting
Rangel Martha, Dr., Phone: 014448262300, Email: gisorangel@gmail.com
Rangel Martha, Dr, Principal Investigator

Hospital Central Dr."IMP", Mexico, San Luis Potosí, Mexico; Recruiting
Rangel Martha, Dr, Phone: 014441981000, Ext: 612, Email: gisorangel@gmail.com
Sánchez Jesús Martín, Dr, Phone: 014448262300, Email: jemarsan7@hotmail.com
Rangel Martha, Dr., Principal Investigator

Additional Information

Starting date: September 2013
Last updated: March 17, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017